Table 2.
Characteristic | Sarcoidosis (N = 30) |
Other DPLDs (N = 18) |
Healthy controls (N = 15) |
P* |
---|---|---|---|---|
CD3+ T cells (% of lymphocytes) | 96.2 (95.3–97.5)## | 92.3 (87.0–94.6) | 92.9 (89.7–94.6) | <0.0001 |
| ||||
CD4/CD8 ratio | 6.1 (4.1–10.8)## | 2.0 (0.5–3.3) | 2.6 (2.1–3.4) | <0.0001 |
| ||||
HLA-DR+ (% of CD4+ T cells) | 75.1 (60.9–80.7) | 76.1 (70.2–84.4)§§ | 44.9 (36.1–56.7) | <0.0001 |
| ||||
HLA-DR+ (% of CD8+ T cells) | 47.3 (42.2–56.3)## | 70.0 (58.6–78.1)§§ | 30.4 (25.9–33.9) | <0.0001 |
| ||||
FoxP3+ (% of CD4+ T cells) | 3.4 (2.1–4.8)## | 7.1 (4.4–12.6) | 5.3 (4.4–7.0) | 0.02 |
| ||||
CD39+ (% of FoxP3+ CD4+ T cells) | 61 (34–78)# | 80 (68–84)§ | 55 (45–66) | 0.51 |
| ||||
CD27+ (% of FoxP3+ CD4+ T cells) | 86 (80–93)# | 95 (87–97)§§ | 78 (72–86) | 0.06 |
Data are shown as median (IQR). *P values represent pairwise comparison between sarcoidosis and healthy controls with Mann-Whitney U test conducted if significant differences were found with Kruskal-Wallis test. § P < 0.05 and §§ P < 0.01 compared to healthy controls. # P < 0.05 and ## P < 0.01 compared to other DPLD.